Pestalozzi advises Celgene on its investment in Anokion
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, completed its $40 million Series B financing. Pestalozzi advised Celgene as to Swiss law.